Intraocular effects of substance P in the rabbit

The intraocular effects of substance P (SP) were studied in rabbits by measuring the pupil diameter, intraocular pressure (IOP), and aqueous humor protein concentration. Most of the animals were pretreated with indomethacin to avoid any interaction with prostaglandins. Intracameral injection of 1 to 150 ng of SP caused strong and persistent miosis without appreciably affecting the aqueous humor protein concentration or IOP. Intracameral injection of 0.8 to 11 micrograms of SP also induced an increase in IOP (7 to 8 mm Hg) without any apparent concomitant disruption in the blood-aqueous barrier. Outflow facility of aqueous humor decreased by a mean value of 50% after intracameral injection of 0.8 to 1.5 microgram of SP. Since the increase in IOP could be prevented by iridectomy, it was probably caused by a pupillary block from the intense miosis induced by SP. No disruption in the blood-aqueous barrier could be detected after intra-arterial infusion of 10 micrograms of SP or intravitreal injection of 100 ng of SP, indicating that the ciliary epithelium was practically insensitive to exogenous SP. Topical as well as subconjunctival administration of up to 1 mg of SP did not cause any irritative response in the eye. The results show that with concentrations of SP causing intense miosis, the eye does not exhibit visible hyperemia and disruption of the blood-aqueous barrier. This finding is consistent with the hypothesis that after certain irritative stimuli, miosis is mediated by a pathway separate from the hyperemia and disruption of the blood-aqueous barrier.     

The ocular hypotensive effects of demeclocycline, tetracycline and other tetracycline derivatives

Demeclocycline, tetracycline and other tetracycline derivatives lowered intraocular pressure (IOP) in rabbits following intravitreal injection, but the onset of this effect was not evident until 1 or more days after drug administration. Of the drugs tested, demeclocycline was the most active ocular hypotensive agent. Demeclocycline caused a dose-dependent decrease in IOP. The maximum IOP decrease of approximately 12 mm Hg occurred 5 days after intravitreal administration of 0.5 mg, with the effect persisting for over a week. Demeclocycline did not alter tonographically measured aqueous humor outflow facility or episcleral venous pressure. Based on calculated aqueous humor flow rates following 0.2 mg demeclocycline, a 62% decrease in aqueous humor formation occurred 7 days after intravitreal injection. The flow-to-diffusion ratio for ascorbate was reduced 54% 6 days after the intravitreal administration of demeclocycline, a change also consistent with suppression of aqueous humor formation. Anterior chamber aqueous humor protein concentration was increased 6 days after demeclocycline administration. No histologic changes were present in the treated eyes by light microscopy. Intravitreal demeclocycline similarly lowered IOP in cats, with the duration of effect lasting up to 20 days.     

Effects of atrial natriuretic factor (ANF) on intraocular pressure and aqueous humor flow in the cynomolgus monkey.

Atrial natriuretic factor (ANF: human sequence) was examined for its effects on basal and terbutaline-stimulated aqueous humor flow, intraocular pressure (IOP) and uveoscleral outflow in cynomolgus monkeys under pentobarbital anesthesia. A dilution method with radioactively labeled albumin was used for the determination of aqueous humor flow. ANF was given by i.v. infusion or intracamerally. Intracameral administration of terbutaline increased the aqueous humor flow significantly; 1.10 +/- 0.05 microliter min-1 in the control eye and 1.69 +/- 0.06 microliter min-1 in the treated eye. I.v. infusion of ANF, 97 fmol kg-1 min-1, increased the aqueous humor flow by about 44% from basal values in the control eye. There was a small but not statistically significant increase on the terbutaline-treated side. The IOP was not changed by ANF at this dose. An ANF dose of 97 pmol kg-1 min-1 increased the aqueous humor flow by 51% in the control eye and by 19% in the terbutaline-treated eye. A further rise of about 8% in aqueous humor flow was registered on the control side when the infused ANF-dose was doubled. Doubling the dose also resulted in a decrease of the IOP by 1.3 +/- 0.3 mmHg on the control side and 2.2 +/- 0.4 mmHg on the terbutaline-stimulated side. Intracameral administration of ANF (81-162 pmol ml-1 perfusion fluid) increased the aqueous humor flow transiently by approximately 50% with a maximum after about 2 hr. The uveoscleral outflow tended to increase and IOP tended to decrease in the ANF-treated eye compared with the control. However, these effects were not statistically significant. These results suggest that ANF may be involved in the control of aqueous humor formation.     

Ocular hypotension induced by electroacupuncture.

The purpose of this study was to investigate the effects of electroacupuncture (EA) on aqueous humor dynamics in rabbits. EA stimulation was performed through two acupuncture needles placed in close proximity to the sciatic nerve. The sites of needle entry were anesthetized. After 1 hr of EA stimulation, intraocular pressure (IOP) decreased and was accompanied by reductions of blood pressure and aqueous humor flow rate. The maximum reduction of IOP was 9 mmHg at 3 hr and decreases in norepinephrine and dopamine levels in aqueous humor occurred simultaneously. In addition, EA stimulation induced an 8-fold increase of endorphin levels in aqueous humor. Ocular hypotension induced by EA lasted for more than 9 hrs and was antagonized by naloxone pretreatment. Furthermore, the EA-induced ocular hypotension was reduced markedly in sympathetically denervated eyes compared with the response of intact, normal eyes. Antagonism of EA-induced ocular hypotension by naloxone, suppression of aqueous humor flow and catecholamine levels by EA and elevation of endorphin levels in aqueous humor by EA indicate that opioids/opiate receptors are involved in modulating ocular hydrodynamics in response to EA.     

Effects of vasoactive intestinal polypeptide (VIP) on intraocular pressure, facility of outflow and formation of aqueous humor in the monkey

Stimulation of the facial nerve causes a non-cholinergic vasodilation in the uvea and a rise in the intraocular pressure in rabbits, cats and monkeys. Vasoactive intestinal polypeptide (VIP) has been suggested as the neurotransmitter mediating these effects. In the present investigation, the effects of VIP on aqueous humor dynamics were studied in cynomolgus monkeys. After intracameral injection of 1 microgram VIP, the outflow facility was higher in the experimental eye than in the control; 0.42 +/- 0.46 compared with 0.33 +/- 0.03 microliter cm H20-1 min-1, difference 0.09 +/- 0.04 microliter cm H2O-1 min-1. Intravenous infusion of VIP, 160 ng min-1, increased aqueous humor flow from 1.12 +/- 0.07 to 1.65 +/- 0.09 microliter min-1. Almost the same effect, a 50% increase in aqueous humor flow, was found after intracameral administration of 90 micrograms VIP. This dose of VIP caused a significant increase in intraocular pressure (IOP) in the experimental eye. The maximal difference in IOP between the experimental eye and the control eye was 7.5 +/- 0.4 cm H2O. A lower dose of VIP, 30 micrograms intracamerally, increased aqueous humor flow by about 20%, but had no consistent effect on IOP. The effect of VIP on aqueous humor flow was not affected by pretreatment with indomethacin. The results suggest that most of the rise in IOP caused by intracameral VIP administration is due to a rise in the pressure in the veins into which the aqueous humor is drained. Enhanced formation of aqueous humor plays a smaller role. The effects of VIP on aqueous humor formation and outflow facility suggest that the facial nerve may be involved in nervous control of aqueous humor dynamics, as VIP is most probably released in the eye by stimulation of the facial nerve.     

Adrenergic mechanism in circadian elevation of intraocular pressure in rabbits.

Stimulation of the ocular sympathetic nerves is essential for the circadian elevation of intraocular pressure (IOP) in rabbits. Adrenergic mechanisms that participate in this elevation of IOP around the onset of darkness were investigated using selective adrenergic agents. Unilateral topical administration of 0.0001-0.1% prazosin, an alpha-1-adrenergic antagonist, at the onset of darkness caused a dose-dependent reduction of IOP elevation. After treatment with 0.1% prazosin, the concentration of norepinephrine (NE) in aqueous humor was not changed, but the aqueous humor protein concentration was reduced. The increase of aqueous flow, determined by fluorophotometry, after the onset of darkness was not affected by 0.1% prazosin treatment. Treatment of rauwolscine, an alpha-2-adrenergic antagonist, or timolol, a beta-adrenergic antagonist, was ineffective in reducing the circadian elevation of IOP. Apraclonidine, an alpha-2-adrenergic agonist, with concentrations of 0.0001-1% caused a dose-dependent reduction of IOP elevation. Treatment with 1% apraclonidine caused a 70% reduction of aqueous humor NE, a significant attenuation of the increase of aqueous flow, and no change of aqueous humor protein concentration. These results suggest that both an increase of aqueous outflow resistance (by alpha-1-adrenergic receptors) and an increase of aqueous flow (not exclusively by beta-adrenergic receptors) contribute to the circadian elevation of IOP. Prejunctional alpha-2-adrenergic receptors may serve as an autoregulating mechanism to limit the excess release of NE and hypertensive spike in IOP.     

Ciclosporin concentration in the rabbit aqueous humor and cornea following subconjunctival administration

The model compound lidocaine was used in the rabbit to investigate different sites of subconjunctival injection for the achievement of reproducible drug concentrations in the aqueous humor. Only epibulbar injections were satisfactory, but not parabulbar or injections under the lower fornix. After epibulbar administration of 0.8 ml 5% ciclosporin, median concentrations in the aqueous humor were 360, 700 and 200 ng/ml after 2, 8, and 24 h, respectively. Corresponding levels in the cornea were 32, 27, and 12 ng/ml. It appears that drug concentrations resulting from epibulbar injections may by therapeutically useful.     

The aqueous humor dynamics and the biphasic response in intraocular pressure induced by guanethidine and adrenaline in the glaucomatous eye

Continuous administration of guanethidine (3%) and adrenaline (0.5%) in one eyedrop (GA) induced a biphasic response of intraocular pressure (IOP). In ten patients with primary open angle and seven glaucoma suspects treated with (GA) twice daily during a 7 month period, tonography, and tonometry were performed and the pupil diameter measured 3 and 8 h post-GA. The combined data of both groups in the hypertensive phase, showed an IOP increase of 2.8 mm Hg (P<0.05), an unchanged coefficient of the outflow, dilated pupil (1.73 mm) (P<0.005) and a 36% increase of aqueous humor production (P<0.02). The specific biphasic course of IOP during treatment with GA seems to be caused by fluctuations in aqueous humor production. The increase in aqueous rate during the hypertensive phase could be related to secondary (rebound) vasodilation in the ciliary body and/or to a transient disruption of the blood-aqueous barrier induced by release of prostaglandins.     

Halothane anesthesia and aqueous humor dynamics in laboratory animals

Halothane anesthesia decreased intraocular pressure (IOP) by approximately 4 mm Hg in both normal rabbits and monkeys. The administration of nitrous oxide or 100% oxygen had no effect on IOP. Although PO2 and PCO2 increased following halothane administration in rabbits, similar blood changes occurred without IOP reduction in control rabbits receiving 100% oxygen. Outflow facility in both species as measured by tonography remained unchanged by halothane administration. Aqueous humor flow as estimated by tonography decreased by about 39% in rabbits and 31% in monkeys. Posterior chamber aqueous humor ascorbate was significantly elevated 90 min after halothane administration in rabbits. The ratio of the aqueous humor flow coefficient to diffusion coefficient for ascorbate (kfa/kdpa) was reduced approximately 47% following the administration of halothane. Halothane did not alter the in vitro accumulation of 131I-hippuran or 86Rb by rabbit ciliary body--iris preparations.     

Angiotensin (1-7) reduces intraocular pressure in the normotensive rabbit eye

PURPOSE: In the present study the effects of exogenous angiotensin II and its breakdown metabolite angiotensin (1-7) on the intraocular pressure (IOP) and on aqueous humor dynamics in normotensive rabbit eye were evaluated. METHODS: Male New Zealand White rabbits with normal IOP were used for intravitreous and topical administration of the test compounds. IOP was measured in conscious rabbits by pneumatonometer after topical anesthesia. Outflow measurements were made with a two-level constant pressure method in anesthetized animals. RESULTS: Angiotensin (1-7) administered intravitreously reduced IOP within 1 to 5 hours (P < 0.05). This effect was abolished by the selective angiotensin (1-7) antagonist A-779, and partially by the selective angiotensin II type 2 receptor antagonist PD123319. When olmesartan, an angiotensin II type 1 receptor blocker, was administered simultaneously with angiotensin (1-7), no antagonism was seen. Intravitreous administration of CGP42112 A, an angiotensin II type 2 receptor agonist, and angiotensin II did not significantly influence IOP, nor did topical administration of these compounds alter IOP. Angiotensin II significantly reduced outflow facility (P < 0.01) dose dependently, whereas angiotensin (1-7) had no effect. CONCLUSIONS: Angiotensin (1-7) is a biologically active vasodilatory and antiproliferative heptapeptide, and its vascular effects counteract those of angiotensin II. It reduces intraocular pressure possibly by a selective Mas receptor, without changing aqueous humor outflow facility in the normotensive rabbit eye.     

Effects of inhibitors of arachidonic acid metabolism on endotoxin-induced ocular inflammation

Rabbits were treated with the cyclooxygenase inhibitors indomethacin (2.5 and 10 mg/kg; IP) or flunixin meglumine (2.2 and 8.8 mg/kg; IM), or the dual cyclooxygenase/lipoxygenase inhibitor BW755C (10 and 30 mg/kg; IP) (administered 4 times over 25 hours). One hour following drug administration, 10 ng of E. coli endotoxin was injected into the vitreal chamber and the subsequent inflammatory response was measured 24 h later. Indomethacin was the most effective inhibitor of prostaglandin (PG) E2 and PGF 2 alpha accumulation in the aqueous humor and their ex vivo production by the lens. It was the only agent that decreased iridal hyperemia and protein concentration in the aqueous humor. Flunixin decreased PG production, although generally to a lesser degree than indomethacin. BW755C produced modest inhibition of PG production in the aqueous humor, but did not affect PG production by the lens. The high dose of BW755C also reduced 5-hydroxyeicosatetraenoic acid (5-HETE) levels in the aqueous humor, but did not alter production by the lens. The results indicate that despite drastic reductions in PG levels in the aqueous humor and PG production by the lens, only modest decreases in aqueous humor protein concentration and iridal hyperemia were achieved. Furthermore, 5-HETE does not appear to be important in the modulation of these inflammatory signs, although it is possible that larger decreases in its production could result in more dramatic effects.     

Intraocular penetration of ketoconazole in rabbits.

We studied penetration of the antifungal agent ketoconazole into the cornea, aqueous humor, and vitreous of rabbits after topical, subconjunctival, and oral administration. The effect of debridement of corneal epithelium on penetration was also investigated. Ketoconazole levels in the cornea and aqueous humor were high after topical or subconjunctival administration, and increased markedly (especially in the cornea) if the corneal epithelium had been debrided before administration of the drug. For example, concentration of ketoconazole in the cornea 1 h after topical drug administration with or without complete corneal epithelial debridement was 44.0 +/- 10.1 and 1,391.5 +/- 130.0 micrograms/g, respectively. Drug levels in the vitreous were not detectable after topical or subconjunctival drug administration, but were improved slightly by prior epithelial debridement (8.3 and 0.12 micrograms/mL after 1 h, respectively). Orally administered ketoconazole resulted in high corneal concentrations (45.0 +/- 7.6 micrograms/g after 1 h) that were still substantial 24 h later (55.0 +/- 7.0 micrograms/g); levels in the aqueous were low.     

改良式前房放液在白内障超声乳化术后早期高眼压中的应用

目的:探讨改良式前房放液法在白内障超声乳化吸出术后早期高眼压的应用价值。方法:对我院3170眼白内障超声乳化吸出术患者中14眼出现术后早期高眼压的患者经过一次性注射器针头轻压角膜侧切口放出部分房水,降低眼压,减轻角膜水肿。结果:经过上述处理后14眼眼压下降为(11.4±5.1)mmHg,角膜透明;视力大于或等于0.7者8眼,0.3～0.5者5眼,0.2者1眼;未出现与改良式前房放液相关并发症。结论:改良式前房放液治疗白内障超声乳化术后早期高眼压简单易行、安全有效,值得推广。     

地塞米松对兔眼房水中一氧化氮及钙离子含量的影响

目的　观测兔眼球结膜下注射地塞米松后其眼压 (P)、房水流畅系数 (C)及房水中一氧化氮 (NO)浓度和Ca2 含量的变化 ,探讨NO、Ca2 在皮质类固醇性青光眼 (GIG)发病中的可能作用。方法　隔日定时给新西兰幼龄白兔双眼球结膜下注射地塞米松 0 5mg ,共 15次 ,3 0d ,隔日定时测定双眼眼压及C值 ,实验结束时抽取房水测定房水中NO及Ca2 浓度。结果　地塞米松使兔眼眼压升高 (P <0 0 5 )、C值及房水中NO浓度下降 (P <0 0 5 ) ;但对兔眼房水中Ca2 的含量无明显影响。结论　眼局部长期应用地塞米松可诱导高眼压 ,引起房水中NO含量显著降低 ,提示NO参与了GIG的发病     

Increased intraocular pressure and hypothermia following injection of calcium into the rabbit third ventricle

Calcium administration into the third ventricle of rabbits resulted in a dose-dependent elevation of intraocular pressure (IOP) and reduction in deep body temperature. These responses were not inhibited by pretreatment with atropine, phentolamine, propanolol or indomethacin. Pretreatment with agents which reduce aqueous humor production, acetazolamide and non-anesthetic doses of phenobarbital, prevented the elevation of IOP but not the induced hypothermia. Imidazole, an agent which alters calcium kinetics, blocked the hypothermia response but not the IOP elevation.     

晚期青光眼的房水动力学变化

目的：观察晚期青光眼高眼压对睫状体功能的损害作用及对角膜透明性的影响。方法：应用扫描荧光光度计及Ｓｃｈｉｏｔｚ电子眼压计分别测定１５只正常眼和１５只晚期原发性青光眼眼压、房水排出率和房水流畅系数,并观察角膜的透明性。结果：晚期青光眼眼房水排出率显著下降,下降程度与眼压水平及病程成正比。房水排出率降低至０．８μｌ／ｍｉｎ。角膜出现水肿混浊,房水排出率下降愈甚,角膜透明性改变愈明显。结论：持续高眼压将     

Contributions of adenosine receptor activation to the ocular actions of epinephrine.

PURPOSE: Epinephrine is an effective drug for glaucoma treatment. However, the mechanisms responsible for the ocular hypotensive action of this compound are not completely understood. Adenosine is an autacoid released by all cells. This study evaluated the role of adenosine receptor activation in epinephrine-induced changes in ocular function. METHODS: Rabbits were pretreated topically with the moderately selective adenosine A1 antagonist 8-(p-sulfophenyl)theophylline (8-SPT) or the adenosine A2 antagonist 3,7-dimethyl-l-propargylxanthine (DMPX). Epinephrine (500 microg) was then administered, and intraocular pressures (IOPs), pupil diameters (PDs), or total outflow facility was evaluated. In a separate group of animals, epinephrine or vehicle was administered, and aqueous humor samples obtained to evaluate changes in aqueous humor purine levels by means of high-performance liquid chromatography. RESULTS: In control animals, epinephrine produced a biphasic change in IOP: an initial rise in IOP of approximately 1 mm Hg from 1/2 to 1 hour followed by significant reduction in IOP of 8 to 9 mm Hg from 3 to 5 hours postadministration. These animals also exhibited a significant increase in PD of 2 to 3 mm from 1/2 to 2 hours postadministration. Pretreatment with 8-SPT (1000 microg) enhanced the initial rise in IOP, while significantly inhibiting the ocular hypotensive response. Pretreatment with 8-SPT also significantly enhanced the epinephrine-induced increase in PD. Inhibition of the epinephrine-induced reduction in IOP by 8-SPT was dose-related with an IC50 of 446 microg. Administration of 8-SPT alone did not significantly alter IOP or PD. The A2 antagonist DMPX did not alter the epinephrine-induced change in IOP or PD. In rabbits pretreated with 8-SPT, the epinephrine-induced increase in outflow facility was significantly reduced by 60% when compared with those in rabbits treated with epinephrine alone. In vehicle-treated rabbits, aqueous humor adenosine and inosine levels were 2.7 +/- 0.38 and 29 +/- 4.2 ng/100 microl, respectively. Three hours after epinephrine administration, adenosine and inosine levels had significantly increased to 11 +/- 1.6 and 66 +/- 4.4 ng/100 microl, respectively. CONCLUSIONS: These results support the idea that in rabbits epinephrine administration stimulates adenosine release in the anterior segment. This rise in endogenous levels of adenosine then leads to the activation of ocular adenosine receptors and is in part responsible for the ocular hypotensive action of epinephrine.     

Effect of flunarizine, a calcium channel blocker, on intraocular pressure and aqueous humor dynamics in monkeys

PURPOSE: To evaluate the effects of flunarizine, a nonselective calcium channel blocker, on intraocular pressure (IOP) in monkeys with laser-induced unilateral glaucoma and on aqueous humor dynamics in normal monkeys. METHODS: The IOP was measured before and hourly for 6 hours after single-dose administration of 0.5%, 1%, or 2% flunarizine to the glaucomatous eye of 8 monkeys with unilateral laser-induced glaucoma. In a separate multiple-dose study, 0.5% flunarizine was applied twice daily for 5 consecutive days to the glaucomatous eye of the same 8 monkeys. IOP was measured at untreated baseline, after treatment with vehicle only, and on treatment days 1, 3, and 5. Tonographic outflow facility and fluorophotometric flow rates of aqueous humor were measured in 7 normal monkeys before and after the fifth dose of twice-daily treatment with 0.5% flunarizine. RESULTS: Unilateral application of 50 microL of 0.5%, 1%, or 2% flunarizine reduced IOP bilaterally. In the treated glaucomatous eyes, flunarizine reduced the IOP for 2, 3, or 5 hours, with a maximum reduction of 2.5+/-0.5 (mean+/-SEM) mm Hg (9%), 3.0+/-0.4 mm Hg (10%), and 5.0+/-0.8 mm Hg (18%) following the 0.5%, 1%, and 2% concentrations, respectively (P<0.01). The maximum reductions in IOP in the contralateral untreated eyes were 1.3+/-0.5 mm Hg, 1.5+/-0.3 mm Hg, and 2.9+/-0.7 mm Hg following the 0.5%, 1%, and 2% concentrations, respectively (P<0.05). Both the magnitude and duration of the ocular hypotensive effect of 0.5% flunarizine were enhanced with twice-daily administration for 5 days. Outflow facility in normal monkey eyes was increased (P<0.05) by 39% in the treated eyes compared with vehicle-treated contralateral eyes and by 41% compared with baseline values, and aqueous humor flow rates were unchanged (P>0.30). CONCLUSIONS: Flunarizine reduces IOP in a dose-dependent manner when administered to glaucomatous monkey eyes, but also has an ocular hypotensive effect on the contralateral untreated eyes. An increase in tonographic outflow facility seems to account for the IOP reduction in normal monkey eyes.     

Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice

PURPOSE: To determine the effect of bimatoprost on intraocular pressure in the prostaglandin FP receptor knockout mouse. METHODS: The IOP response to a single 1.2-microg (4 microL) dose of bimatoprost was measured in the treated and untreated fellow eyes of homozygote (FP+/+, n = 9) and heterozygote (FP+/-, n = 10) FP-knockout mice, as well as in wild-type C57BL/6 mice (FP+/+, n = 20). Serial IOP measurements were also performed after topical bimatoprost in a separate generation of homozygous FP-knockout mice and wild-type littermate control animals (n = 4 per group). Aqueous humor protein concentrations were measured to establish the state of the blood-aqueous barrier. Tissue, aqueous humor and vitreous concentrations of bimatoprost, latanoprost, and their C-1 free acids were determined by liquid chromatography and tandem mass spectrometry. RESULTS: A significant reduction in IOP was observed in the bimatoprost-treated eye of wild-type mice at 2 hours, with a mean difference and 95% confidence interval (CI) of the difference in means of -1.33 mm Hg (-0.81 to -1.84). Bimatoprost did not lead to a significant reduction in IOP in either the heterozygous knockout -0.36 mm Hg (-0.82 to +0.09) or homozygous FP-knockout mice 0.25 mm Hg (-0.38 to +0.89). The lack of an IOP response in the FP-knockout mice was not a consequence of blood-aqueous barrier breakdown, as there was no significant difference in aqueous humor protein concentration between treated and fellow eyes. Tissue and aqueous humor concentrations of bimatoprost, latanoprost, and their C-1 free acids indicate that latanoprost, but not bimatoprost, is hydrolyzed in the mouse eye after topical administration. CONCLUSIONS: An intact FP receptor gene is critical to the IOP response to bimatoprost in the mouse eye.     

Effects of systemic desmopressin on aqueous humor dynamics in rabbits

Intravenous desmopressin, a synthetic antidiuretic hormone, resulted in a dose-dependent increase in intraocular pressure (IOP) in rabbits. IOP was increased 3.6 +/- 0.8 mm Hg 6 hr following injection of desmopressin 200 mUnits/kg with the increase lasting over 10 hr. IOP returned to baseline 24 hr after the injection. Systemic blood pressure, plasma osmolarity and arterial blood gases were not altered by desmopressin. The increased IOP was not associated with alterations in measured outflow facility or episcleral venous pressure. Five hours after desmopressin injection, calculated aqueous humor flow was increased approximately 57%. Aqueous humor ascorbate measurements for calculation of flow to diffusion ratios and anterior chamber fluorophotometry also were consistent with an increased rate of aqueous humor formation as the mechanism for the IOP elevation. Desmopressin administration did not increase aqueous humor protein or aqueous humor cyclic AMP concentration. Systemic pretreatment with indomethacin only partially blocked the IOP increase. Systemic pretreatment with demeclocycline completely blocked the desmopressin-induced increase in IOP.